Motoaki Yasukawa1, Takeshi Kawaguchi2, Norikazu Kawai2, Takashi Tojo2, Shigeki Taniguchi2. 1. Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan myasukawa@naramed-u.ac.jp. 2. Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.
Abstract
BACKGROUND/AIM: Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyze the outcomes of pulmonary metastasectomy for PDAC. PATIENTS AND METHODS: A retrospective case-control study of patients undergoing pulmonary metastasectomy for isolated lung metastasis of PDAC between 2004 and 2016. Clinicopathological features were analyzed and survival curves were plotted using the Kaplan-Meier method. RESULTS: Twelve patients were included. The median follow-up period after metastasectomy was 33 months. At the time of analysis, five patients had deceased, two were alive with disease, and five were alive without disease. The median survival time after pulmonary metastasectomy was 47 months. The estimated 3- and 5-year overall survival rates were 62.3% (95%CI=27.8-84.0) and 31.2% (95%CI=1.7-71.7). CONCLUSION: Outcomes were favorable following pulmonary metastasectomy in selected patients with PDAC. Copyright
BACKGROUND/AIM: Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyze the outcomes of pulmonary metastasectomy for PDAC. PATIENTS AND METHODS: A retrospective case-control study of patients undergoing pulmonary metastasectomy for isolated lung metastasis of PDAC between 2004 and 2016. Clinicopathological features were analyzed and survival curves were plotted using the Kaplan-Meier method. RESULTS: Twelve patients were included. The median follow-up period after metastasectomy was 33 months. At the time of analysis, five patients had deceased, two were alive with disease, and five were alive without disease. The median survival time after pulmonary metastasectomy was 47 months. The estimated 3- and 5-year overall survival rates were 62.3% (95%CI=27.8-84.0) and 31.2% (95%CI=1.7-71.7). CONCLUSION: Outcomes were favorable following pulmonary metastasectomy in selected patients with PDAC. Copyright
Authors: Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim Journal: Clin Exp Metastasis Date: 2021-01-24 Impact factor: 5.150
Authors: Thomas L Sutton; Aaron Grossberg; Frederick Ey; Eileen M O'Reilly; Brett C Sheppard Journal: Cancer Biol Ther Date: 2021-10-25 Impact factor: 4.742
Authors: Jason M Link; Shannon M Liudahl; Courtney B Betts; Shamilene Sivagnanam; Kenna R Leis; Mary McDonnell; Carl R Pelz; Brett Johnson; Kelly J Hamman; Dove Keith; Jone E Sampson; Terry K Morgan; Charles D Lopez; Lisa M Coussens; Rosalie C Sears Journal: JCO Precis Oncol Date: 2021-02-05
Authors: Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Martijn R Meijerink; Hester J Scheffer Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639